Latest Trastuzumab Stories
Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab.
Results from the initial analysis of event-free and overall survival for patients enrolled in the randomized, phase III Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization (NeoALTTO) trial are to be presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10–14.
Giving trastuzumab and anthracyclines at the same time is effective at treating HER-2-positive breast cancer, but there is concern that this combination can be associated with an increased risk of cardiac toxicity.
RnRMarketResearch.com adds Latest Report on “Monoclonal Antibodies Market in Breast Cancer to 2019 – Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth” to its store.
- an ornament or knob in the shape of a flower